Introduction
============

Hepatocellular carcinoma (HCC) is a common malignancy and the leading cause of cancer-related mortality, with an estimated 42,220 new cases diagnosed and 30,200 mortalities in the United States in 2018 ([@b1-mmr-20-03-2519]). Despite curative surgical resection and recent advances in adjuvant chemotherapy, radiotherapy and liver transplantation, recurrence and metastasis occur frequently, leading to the overall 5-year survival rate \<20% ([@b2-mmr-20-03-2519]). Although multiple factors have been linked to the development and progression of HCC, hepatitis virus infection is considered to be the predominant underlying cause. It has been reported that the burden of HCC parallels the prevalence of hepatitis C virus (HCV) ([@b3-mmr-20-03-2519]). The 10-year survival rate was reported to be approximately 35% in HCC patients with HCV ([@b4-mmr-20-03-2519]). Thus, it is necessary to explore the molecular mechanisms of HCV-associated hepatocarcinogenesis to screen novel prognostic biomarkers and to develop effective therapeutic strategies.

Although the mechanism of the pathogenesis by which HCV induces HCC is currently unclear, epigenetic changes (such as DNA methylation) have been demonstrated to serve fundamental roles. For example, aberrant hypermethylation of tumor suppressor genes or hypomethylation of proto-oncogenes may result in the decrease or increase in their expression levels and induce excessive proliferation, migration and invasion of hepatocytes ([@b5-mmr-20-03-2519]). Methylation of several genes has been reported in HCV-associated HCC ([@b6-mmr-20-03-2519]). For example, Ramadan *et al* demonstrated that the frequency of aberrant methylation in the promoter region of serine protease inhibitor kunitz-type 2 gene was significantly higher in HCV-positive HCC cases compared with HCV-positive cirrhosis and normal control patients ([@b7-mmr-20-03-2519]). Takagi *et al* reported that CpG islands in zygote arrest 1 exon 1 had a higher methylation level in HCV-positive HCC compared with non-tumorous tissues ([@b8-mmr-20-03-2519]). Tsunedomi *et al* not only demonstrated a correlation between DNA methylation and mRNA expression levels of ATP-binding cassette subfamily B member 6 (ABCB6), but also revealed that aberrant mRNA and DNA methylation levels of ABCB6 may serve as predictive biomarkers for early intrahepatic recurrence of HCV-positive HCC ([@b9-mmr-20-03-2519]). *In vitro* studies by Mileo *et al* ([@b10-mmr-20-03-2519]) and Quan *et al* ([@b11-mmr-20-03-2519]) demonstrated that HCV may promote the progression of HCC cells by downregulating the protein and mRNA levels of proline rich protein BstNI subfamily 2/p130 and secreted frizzled-related protein, a Wnt antagonist, by inducing promoter hypermethylation. However, genes with aberrant DNA methylation for HCV-positive HCC remain largely under-investigated.

The aim of the present study was to identify novel genes to explain the development of HCV-positive HCC by combining mRNA expression profile and methylation profile microarrays, and to confirm their transcriptional and translational expression using The Cancer Genome Atlas (TCGA) datasets and Human Protein Atlas database (HPA). The results of the present study may provide novel therapeutic targets for HCV-positive HCC.

Materials and methods
=====================

### Microarray data collection

Three microarray datasets: GSE19665 ([@b12-mmr-20-03-2519]), GSE62232 ([@b13-mmr-20-03-2519]) and GSE60753 ([@b14-mmr-20-03-2519]) were downloaded from the Gene Expression Omnibus database (<http://www.ncbi.nlm.nih.gov/geo>) on July 25, 2018. The GSE19665 dataset \[platform, GPL570 Affymetrix Human Genome U133 Plus 2.0 Array (HG-U133_Plus_2)\] was used to analyze the gene expression profile in 20 HCC and 20 matched non-cancerous tissues, among which 5 pairs were HCV-positive; the GSE62232 dataset (platform, HG-U133_Plus_2) was used to detect the gene expression profile in 81 HCC (including 9 HCV-positive) and 10 normal liver tissues; and the GSE60753 dataset (platform, GPL13534, Illumina HumanMethylation450 BeadChip) was used to determine the DNA methylation profile in 156 HCC (including 12 HCV-positive), 34 normal liver tissues and 1 HCC cell line. Normal liver tissues were not matched with HCC in GSE62232 and GSE60753, but only collected from patients without HCC (such as benign cysts). Only the HCV-positive HCC and normal control samples were used for our following analyses.

### Microarray data preprocessing

For the GSE19665 and GSE62232 datasets, the raw data were preprocessed using the oligo package (version 1.42.0; <http://www.bioconductor.org/packages/release/bioc/html/oligo.html>) in Bioconductor R package (version 3.4.1; <http://www.R-project.org>), including data transformation, missing value imputation with median, background correction with microarray analysis suite method and quantile normalization. For the GSE60753 dataset, the DNA methylation β values were downloaded and the genes were annotated according to the annotation information from the corresponding platform.

### Differential gene expression and methylation analysis

Differentially expressed genes (DEGs) and differentially methylated genes (DMGs) between HCV-positive HCC and control samples were identified using the Linear Models for Microarray Data method (version 3.34.0; <http://bioconductor.org/packages/release/bioc/html/limma.html>) ([@b15-mmr-20-03-2519]) in the Bioconductor R package. False discovery rate (FDR) \<0.05 and \|logFC\| \>1 were defined as the statistical threshold value; where FC is fold change. Hierarchical clustering ([@b16-mmr-20-03-2519]) was performed for the DEGs and DMGs using pheatmap R package (version 1.0.8; <http://cran.r-project.org/web/packages/pheatmap>) based on Euclidean distance and the results were displayed as a heat map. The upregulated and downregulated shared DEGs in GSE19665 and GSE62232 datasets were then overlapped with the hypomethylated and hypermethylated DMGs, respectively, to identify the methylated-mediated genes. Additionally, the methylated-mediated genes were compared with the human oncogenes downloaded from the ONGene database (<http://ongene.bioinfo-minzhao.org>) ([@b17-mmr-20-03-2519]) to screen for HCC-related oncogenes.

### Protein-protein interaction (PPI) network construction and module analysis

The STRING database (version 10.0; <http://string-db.org>) ([@b18-mmr-20-03-2519]) was used to predict the interactions between DEGs, and a PPI network was constructed using the obtained interaction pairs using the Cytoscape software (version 3.6.1; <http://www.cytoscape.org>) ([@b19-mmr-20-03-2519]). The topological characteristics of the nodes (proteins) in the PPI network were computed using the CytoNCA plugin in the Cytoscape software (<http://apps.cytoscape.org/apps/cytonca>) ([@b20-mmr-20-03-2519]) to determine the hub genes, including 'degree' \[the number of edges (interactions) of a node (protein)\], 'betweenness' (the number of shortest paths that run through a node), 'closeness centrality' (CC; the average length of the shortest paths to access all other proteins in the network) and 'average path length' (APL; the average distance between all pairs of nodes). Functionally related modules with well-interconnected genes were further identified in the PPI network using the Molecular Complex Detection (MCODE; version 1.4.2; <http://apps.cytoscape.org/apps/mcode>) algorithm ([@b21-mmr-20-03-2519]) with the following scoring options: Degree cutoff=2; node score cutoff=0.2; K-core=2. Modules with MCODE score (Density\*Nodes) \>3 and node number \>6 were considered to be significant.

### Function enrichment analysis

Gene Ontology (GO) biological process terms and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were performed for the methylated-mediated DEGs using the Database for Annotation, Visualization and Integrated Discovery (DAVID) online tool (version 6.8; <http://david.abcc.ncifcrf.gov>) ([@b22-mmr-20-03-2519]) and BinGO ([@b23-mmr-20-03-2519]) plugin in Cytoscape to predict their underlying functions. Statistical significance was defined as P\<0.05 or FDR \<0.05.

### Validation of the selected methylation-mediated DEGs

The mRNA and methylation sequencing data of HCC tissues and normal liver tissues from patients without HCC were extracted from TCGA database (<https://portal.gdc.cancer.gov>) prior to July 25, 2018, which were measured on the Illumina HiSeq 2000 RNA Sequencing platform. Only the HCV-positive HCC samples were included in the present study to confirm the expression consistency of the methylated-mediated DEGs. The expression difference between HCC and controls was determined by Student\'s independent t-test using the TCGA data. P\<0.05 was considered to indicate a statistically significant difference.

In addition, protein expression levels of the methylated-mediated DEGs were also validated by the HPA database (version 18; <http://www.proteinatlas.org>) ([@b24-mmr-20-03-2519]), which was used to evaluate the translational levels of the DEGs by immunohistochemistry. Results are presented as the sum of scores of staining intensity (negative, weak, moderate or strong) and the percentage of stained cells (\<25, 25--75 or \>75%): Negative-not detected; weak + \<25%-not detected; weak + 25--75 or 75%-low; moderate \<25%-low; moderate + 25--75 or 75%-medium; strong \<25%-medium, strong + 25--75 or 75%-high.

Results
=======

### Differential gene expression and methylation

A flowchart depicting the analytical process is presented as [Fig. 1](#f1-mmr-20-03-2519){ref-type="fig"}. Following preprocessing, a total of 1,306 (735 downregulated and 571 upregulated) and 1,249 (330 downregulated and 919 upregulated) DEGs were identified between HCV-positive HCC and control tissues in GSE19665 and GSE62232 datasets, respectively, using the cut-off criteria FDR \<0.05 and \|logFC\| \>1. The hierarchical-clustering heat map ([Fig. 2A and B](#f2-mmr-20-03-2519){ref-type="fig"}) indicated that DEGs may be used to distinguish HCV-positive HCC from control samples.

A total of 23,408 methylated probes were annotated to genes in the GSE60753 dataset. By comparing with normal samples, 1,448 DMGs (903 hypomethylated and 545 hypermethylated) were also obtained in HCV-positive HCC tissues. The hierarchical-clustering heat map ([Fig. 2C](#f2-mmr-20-03-2519){ref-type="fig"}) revealed that DMGs were different between HCV-positive HCC and control samples.

Following comparison of the DEGs identified in GSE19665 and GSE62232 datasets, 173 downregulated and 278 upregulated DEGs were revealed to be common and their expression trends were consistent in the two datasets ([Fig. 3A](#f3-mmr-20-03-2519){ref-type="fig"}). Further integration with the DMGs found 122 DEGs were downregulated by DNA hypermethylation and 63 DEGs were upregulated by DNA hypomethylation ([Fig. 3B](#f3-mmr-20-03-2519){ref-type="fig"}). Among the methylated DEGs, nine were suggested as human oncogenes according to the prediction by ONGene database; five were downregulated: Inhibitor of DNA binding 1, HLH protein (ID1), epithelial cell adhesion molecule (EPCAM), Fos proto-oncogene, AP-1 transcription factor subunit (FOS), ID2 and placenta specific 8 (PLAC8), whereas four were upregulated: Aurora kinase A (AURKA), ubiquitin conjugating enzyme E2 C (UBE2C), erb-b2 receptor tyrosine kinase 3 (ERBB3) and cyclin-dependent kinase inhibitor 3 (CDKN3).

### Functional enrichment for the DEGs

The 122 downregulated/hypermethylated and 63 upregulated/hypomethylated DEGs were respectively uploaded to DAVID to predict their functions. Using the threshold value of FDR \<0.05, 18 GO biological process terms were obtained for the downregulated/hypermethylated DEGs, including 'response to wounding' (FOS) and 'inflammatory response' (FOS), whereas 14 GO biological process terms were enriched for the upregulated/hypomethylated DEGs, including 'cell cycle process' (AURKA, CDKN3 and UBE2C) and 'cell cycle' (CDKN3 and MCM6) ([Fig. 4A](#f4-mmr-20-03-2519){ref-type="fig"}; [Table I](#tI-mmr-20-03-2519){ref-type="table"}). Furthermore, KEGG pathway enrichment analysis was also performed, which resulted in 11 KEGG pathways identified as enriched for downregulated/hypermethylated and 4 enriched for upregulated/hypomethylated DEGs, using the threshold value of P\<0.05 (FDR \>0.05 for all pathways) ([Fig. 4B](#f4-mmr-20-03-2519){ref-type="fig"}; [Table II](#tII-mmr-20-03-2519){ref-type="table"}). The KEGG pathway enrichment results were consistent with GO biological process term analysis, in which inflammatory-related 'cytokine-cytokine receptor interaction' pathway was enriched for downregulated/hypermethylated DEGs, and 'DNA replication' and 'cell cycle' were enriched for upregulated/hypomethylated DEGs.

### PPI network

The STRING database identified interaction relationships in 105 out of the 185 methylation-related DEGs (68 downregulated and 37 upregulated). The 211 interaction relationship pairs among the DEGs were used to construct a PPI network ([Fig. 5A](#f5-mmr-20-03-2519){ref-type="fig"}); seven of the previously identified human oncogenes were included (downregulated, ID1, FOS and EPCAM; upregulated, AURKA, CDKN3, UBE2C and ERBB3), as no interactions with other DEGs were identified for ID2 and PLAC8.

Two human oncogenes, FOS and CDKN3, were indicated as hub genes of the PPI network as they were shared and ranked in the top 15 for 4 topological characteristics ([Table III](#tIII-mmr-20-03-2519){ref-type="table"}). In addition, AURKA and UBE2C ranked top 5 in 'degree'. ID1 was one of the top 10 genes in 'CC' and 'APL'.

Subsequently, four highly connected PPI sub-modules ([Fig. 5B](#f5-mmr-20-03-2519){ref-type="fig"}) were extracted from the overall PPI network using MCODE. BinGO enrichment analysis demonstrated that the genes in module 1 (MCODE score=12.81) were involved in mitotic cell cycle (AURKA, CDKN3 and UBE2C); the genes in module 2 (MCODE score=5.067) were associated with detoxification of copper ions; the genes in module 3 (MCODE score=3.771) participated in the regulation of cell migration; and the genes in module 4 (MCODE score=3.41) were associated with carboxylic acid metabolic process ([Table IV](#tIV-mmr-20-03-2519){ref-type="table"}).

### Validation of the selected methylation-mediated DEGs

Based on the enrichment and PPI analyses, it was hypothesized that downregulated/hypermethylated FOS and ID1 and upregulated/hypomethylated CDKN3, AURKA and UBE2C may be important human oncogenes for HCV-positive HCC. To further confirm their expression and methylation levels, the mRNA and methylation sequencing data of 58 HCV-HCC tissues and 50 normal controls were obtained from the TCGA database. The results demonstrated that the transcriptional expression and methylation levels of FOS, CDKN3 and AURKA in TCGA sequencing data ([Fig. 6B](#f6-mmr-20-03-2519){ref-type="fig"}) were consistent with the microarray data ([Fig. 6A](#f6-mmr-20-03-2519){ref-type="fig"}). However, the methylation level of UBE2C was not significantly different between HCV-positive HCC and normal control TCGA samples, although its expression level was consistent between TCGA sequencing data and our used microarray data ([Fig. 6](#f6-mmr-20-03-2519){ref-type="fig"}). The methylation level of ID1 had a detection value of 0 in the TCGA and thus comparison was not performed.

In addition, the HPA database was used to confirm the protein expression level of the genes in HCC by immunohistochemistry. Protein expression levels of AURKA in HCC tissues were higher, whereas protein expression levels of FOS in HCC tissues were lower compared with normal hepatocytes ([Fig. 7](#f7-mmr-20-03-2519){ref-type="fig"}). There was no immunohistochemical result for CDKN3 in the HPA database and no difference was observed in UBE2C and ID1 protein expression levels between HCC and normal control tissues.

Discussion
==========

Through comprehensive analysis and validation, results from the present study indicated that AURKA and FOS may be crucial genes involved in HCV-positive HCC by participating in the cell cycle process and inflammatory response. HCV may upregulate the expression of AURKA and downregulate FOS by changes in DNA methylation.

HCV stimulates excessive cell proliferation in hepatocytes by dysregulating the cell cycle, which induces the development of HCC ([@b25-mmr-20-03-2519],[@b26-mmr-20-03-2519]). Several positive cell cycle regulators (such as cyclin D1, cyclin E and Rb/p105) have been identified to be upregulated, whereas negative regulators \[such as cyclin-dependent kinase 4 (CDK4), CDK6, p21Cip1, p27Kip1 and p57Kip2) are downregulated in patients with HCV-positive HCC compared with patients with chronic hepatitis C with or without liver cirrhosis ([@b27-mmr-20-03-2519]). AURKA, which is located on chromosome 20q13.2, encodes a serine/threonine kinase involved in the assembly and maintenance of the mitotic spindle ([@b28-mmr-20-03-2519]). Thus, AURKA is speculated to be a crucial gene for the regulation of cell cycle and carcinogenesis in several cancer types, including HCC ([@b29-mmr-20-03-2519]). Yang *et al* demonstrated that knockdown of AURKA suppressed the growth of ovarian cancer cells by reducing centrosome amplification, malformation of mitotic spindles, and chromosome aberration ([@b30-mmr-20-03-2519]). Additionally, restoring the expression of p21 and pRb attenuated the effects of AURKA silencing on cell cycle progression ([@b30-mmr-20-03-2519]). Using RNA microarray and reverse transcriptase-quantitative PCR analysis, Zhou *et al* reported that AURKA was significantly upregulated in human urothelial carcinoma compared with normal urothelium ([@b31-mmr-20-03-2519]) and demonstrated that AURKA inhibitor MLN8237 induced cell-cycle arrest, aneuploidy, mitotic spindle failure and apoptosis in human bladder cancer cells, which arrested tumor growth ([@b31-mmr-20-03-2519]). Li *et al* also used the MLN8237 to demonstrate that AURKA regulated cell cycle in breast cancer cells by modulating the p53/p21/cell division control 2/cyclin B1 pathway ([@b32-mmr-20-03-2519]). Similarly, the verification experiments demonstrated that AURKA inhibitor alisertib arrested HCC cells in G2/M phase and induced an accumulation of aneuploidy by regulating the expression of key cell cycle regulators such as cyclin B1 ([@b33-mmr-20-03-2519],[@b34-mmr-20-03-2519]). The present study demonstrated that AURKA was highly expressed at the mRNA and protein levels in HCV-positive HCC. In addition to the cell cycle, a recent study has suggested that AURKA contributes to tumor migration, invasion, epithelial mesenchymal transition and cancer stem cell behaviors, which also have been preliminarily validated in HCC ([@b35-mmr-20-03-2519]), but not HCV-related HCC. Thus, further investigation of the roles of AURKA in HCV-related HCC remains necessary.

DNA methylation is an important mechanism for regulating gene expression epigenetically. Hypermethylation of genes is associated with reduced expression, whereas hypomethylation is associated with increased expression. Thus, high expression of AURKA in HCV-positive HCC was predicted to be due to hypomethylation, which was validated by the microarray and TCGA data. This conclusion agreed with a previous study on esophageal cancer, in which AURKA methylation and human papillomavirus infection was higher in precancer, esophagitis and normal tissues compared with cancer tissues ([@b36-mmr-20-03-2519]). However, further experiments are needed to confirm the effects of HCV on the methylation of AURKA and the development of HCC.

FOS is a member of the fos family of transcription factors, which has been extensively demonstrated to be a pro-oncogenic gene and promote proliferation, invasion and metastasis of cancer through AP-1-related mechanisms, including HCV-positive HCC ([@b37-mmr-20-03-2519]). However, in the present study, FOS was downregulated and hypermethylated. This may indicate that FOS may be a dual-function gene, which has been identified in other cancers, such as ovarian cancer ([@b38-mmr-20-03-2519]) and pancreatic cancer ([@b39-mmr-20-03-2519]). Alternatively, the results may be negative due to the small sample size. Further studies with larger sample sizes are needed to confirm role of FOS in HCV-positive HCC.

There were certain limitations to the present study. First, although the known microarray and TCGA sequencing data were included to confirm the expression and methylation levels of crucial genes, the sample size associated with HCV-positive HCC was small. Therefore, more clinical samples need to be collected to further confirm their expression levels. Second, although the present study has suggested that the expression levels of AURKA and FOS may be regulated by methylation, additional *in vitro* and *in vivo* experiments using a methylation inhibitor, such as 5-azacytidine, are essential to verify these results. Third, HCV infection-related *in vitro* and *in vivo* experiments (accompanied with overexpression or knockdown of genes) are also needed to demonstrate the functional roles of AURKA and FOS in cell proliferation, apoptosis, migration and invasion.

The results of the present study preliminarily indicate that aberrantly methylated AURKA and FOS may be potential therapeutic targets for treatment of HCV-positive HCC.
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![Analysis plan. The key genes were determined by integrating the methylation and mRNA expression profile microarray datasets and then confirmed using TCGA and HPA data. DAVID, Database for Annotation, Visualization and Integrated Discovery; DEGs, differentially expressed genes; DMGs, differentially methylated genes; GEO, Gene Expression Omnibus; GO, Gene Ontology; HPA, Human Protein Atlas; KEGG, Kyoto Encyclopedia of Genes and Genomes; limma, Linear Models for Microarray Data; PPI, protein-protein interaction; TCGA, The Cancer Genome Atlas.](MMR-20-03-2519-g00){#f1-mmr-20-03-2519}

![Differentially expressed and methylated genes in HCV-positive HCC. (A-C) Hierarchical clustering and heat map analysis of differentially expressed genes in (A) GSE19665 and (B) GSE62232 and of (C) differentially methylated genes in GSE60753. Red, high expression (or hypermethylation); green, low expression (or hypomethylation). HCC hepatocellular carcinoma; HCV, hepatitis C virus.](MMR-20-03-2519-g01){#f2-mmr-20-03-2519}

![Shared DEGs in GSE19665 and GSE62232 hepatitis C virus-positive hepatocellular carcinoma datasets. (A and B) Venn diagrams demonstrate (A) shared DEGs in GSE19665 and GSE62232 and (B) their association with DMGs in GSE60753. DEGs, differentially expressed genes; DMGs, differentially methylated genes.](MMR-20-03-2519-g02){#f3-mmr-20-03-2519}

![GO and KEGG enrichment analyses of the methylation-related DEGs. (A) GO biological process term analysis. Triangles indicate the significance level (P-value adjusted to FDR). (B) KEGG pathway enrichment. Left, downregulated/hypermethylated DEGs; right, upregulated/hypomethylated DEGs. DEGs, differentially expressed genes; FDR, false discovery rate; GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes.](MMR-20-03-2519-g03){#f4-mmr-20-03-2519}

![PPI network of the methylation-related differentially expressed genes. (A) An overall PPI network constructed using the protein interaction data from the STRING 10.0 database. (B) Functional highly connected sub-modules extracted from the PPI network using the Molecular Complex Detection plugin of Cytoscape software. Red, upregulated genes; green, downregulated genes; circled genes are known human oncogenes. AURKA, aurora kinase A; CDKN3, cyclin-dependent kinase inhibitor 3; EPCAM, epithelial cell adhesion molecule; ERBB3, erb-b2 receptor tyrosine kinase 3; FOS, Fos proto-oncogene, AP-1 transcription factor subunit; ID1, inhibitor of DNA binding 1, HLH protein; M1, module 1; M2, module 2; M3, module 3; M4, module 4; PPI, protein-protein interaction; UBE2C, ubiquitin conjugating enzyme E2 C.](MMR-20-03-2519-g04){#f5-mmr-20-03-2519}

![Validation of the hub genes in the samples obtained from TCGA database. (A) Gene expression and methylation levels in samples of microarray datasets GSE19665 (HCV-positive HCC tissues, n=5; normal controls, n=5), GSE62232 (HCV-positive HCC tissues, n=9; normal controls, n=10) and GSE60753 (HCV-positive HCC tissues, n=29; normal controls, n=34). (B) Gene expression and methylation levels in TCGA data (HCV-positive HCC tissues, n=58; normal controls, n=50). Student\'s independent t-test was used to analyze the differences between HCV-positive HCC and normal controls. \*P\<0.05, \*\*P\<0.01 and \*\*\*P\<0.001 vs. control. AURKA, aurora kinase A; CDKN3, and cyclin-dependent kinase inhibitor 3; FOS, Fos proto-oncogene, AP-1 transcription factor subunit; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; ID1, inhibitor of DNA binding 1, HLH protein; UBE2C, ubiquitin conjugating enzyme E2 C; n.s., not significant; TCGA, The Cancer Genome Atlas.](MMR-20-03-2519-g05){#f6-mmr-20-03-2519}

![Validation of the hub genes at a translational level using the Human Protein Atlas database. AURKA, aurora kinase A; FOS, Fos proto-oncogene, AP-1 transcription factor subunit; HCC, hepatocellular carcinoma; ID1, inhibitor of DNA binding 1, HLH protein; UBE2C, ubiquitin conjugating enzyme E2 C.](MMR-20-03-2519-g06){#f7-mmr-20-03-2519}

###### 

GO enrichment for methylation-related differentially expressed genes.

  A, Downregulated/hypermethylated genes                                                                     
  ----------------------------------------- -------------------------------------------------- ------------- ------------------------------------------------------------------------------------------------------
  0051605                                   Protein maturation by peptide bond cleavage        2.87×10^−2^   CFP, C8B, C7, FCN3, KLKB1, C1R
  0048545                                   Response to steroid hormone stimulus               1.47×10^−2^   PRSS8, FOS, GOT1, CCL2, ACADS, WFDC1, CA2, NPY1R, GHR
  0046395                                   Carboxylic acid catabolic process                  2.18×10^−2^   ASPA, GOT1, ACADS, IDO2, KMO, UROC1, PON3
  0045087                                   Innate immune response                             2.26×10^−3^   CFP, C8B, C7, FCN3, IL1RAP, VNN1, C1R, CD1D, GCH1
  0031960                                   Response to corticosteroid stimulus                2.93×10^−2^   PRSS8, FOS, GOT1, CCL2, ACADS, GHR
  0019439                                   Aromatic compound catabolic process                2.70×10^−2^   EPHX2, IDO2, KMO, PON3
  0016054                                   Organic acid catabolic process                     2.18×10^−2^   ASPA, GOT1, ACADS, IDO2, KMO, UROC1, PON3
  0010817                                   Regulation of hormone levels                       4.64×10^−2^   ALDH8A1, SHBG, LY6E, CRHBP, CYP26A1, SRD5A1, BCO2
  0009725                                   Response to hormone stimulus                       2.54×10^−2^   PRSS8, FOS, GOT1, CCL2, HMGCS2, ACADS, FBP1, WFDC1, CA2, NPY1R, GHR
  0009719                                   Response to endogenous stimulus                    4.10×10^−2^   PRSS8, FOS, GOT1, CCL2, HMGCS2, ACADS, FBP1, WFDC1, CA2, NPY1R, GHR
  0009611                                   Response to wounding                               1.02×10^−3^   C7, CCL2, HPS5, EPHX2, CHST4, C1R, CFP, C8B, FOS, LPA, PLSCR4, FCN3, KLKB1, IL1RAP, PROZ, VNN1, NGFR
  0006959                                   Humoral immune response                            2.46×10^−2^   CFP, C8B, C7, CCL2, FCN3, C1R
  0006956                                   Complement activation                              2.70×10^−2^   CFP, C8B, C7, FCN3, C1R
  0006955                                   Immune response                                    6.96×10^−3^   C7, CCL2, CHST4, C1R, VIPR1, CXCL12, CD1D, GCH1, CFP, C8B, FCN3, HAMP, IL1RAP, VNN1
  0006954                                   Inflammatory response                              5.26×10^−3^   CFP, C8B, FOS, C7, CCL2, FCN3, KLKB1, IL1RAP, EPHX2, VNN1, C1R, CHST4
  0006952                                   Defense response                                   1.98×10^−2^   C7, CCL2, EPHX2, CHST4, C1R, CD1D, GCH1, CFP, C8B, FOS, FCN3, HAMP, KLKB1, IL1RAP, VNN1
  0006575                                   Cellular amino acid derivative metabolic process   2.47×10^−2^   GGT5, LY6E, IDO2, VNN1, KMO, BBOX1, GHR, GCH1
  0002526                                   Acute inflammatory response                        3.37×10^−3^   CFP, C8B, C7, FCN3, KLKB1, EPHX2, VNN1, C1R
                                                                                                             
  **B, Upregulated/hypomethylated genes**                                                                    
                                                                                                             
  **GO ID**                                 **GO term**                                        **FDR**       **Genes**
                                                                                                             
  0051726                                   Regulation of cell cycle                           3.52×10^−2^   TP53BP2, NUSAP1, SFN, CDKN3, UBE2C
  0051301                                   Cell division                                      4.37×10^−2^   RAD21, NUSAP1, NDC80, PARD3B, CEP55, UBE2C, CDCA3
  0022616                                   DNA strand elongation                              4.65×10^−2^   RFC4, FEN1
  0022403                                   Cell cycle phase                                   3.99×10^−2^   RAD21, NUSAP1, NDC80, AURKA, CEP55, CDKN3, UBE2C, CDCA3
  0022402                                   Cell cycle process                                 2.27×10^−2^   RAD21, NUSAP1, NDC80, AURKA, CEP55, CDKN3, UBE2C, CDCA3
  0007067                                   Mitosis                                            3.63×10^−2^   RAD21, NUSAP1, NDC80, AURKA, CEP55, UBE2C, CDCA3
  0007049                                   Cell cycle                                         3.98×10^−2^   RAD21, TP53BP2, E2F8, NUSAP1, NDC80, AURKA, PARD3B, CEP55, CDKN3, UBE2C, CDCA3, MCM6
  0006271                                   DNA strand elongation during DNA replication       4.22×10^−2^   RFC4, FEN1
  0006261                                   DNA-dependent DNA replication                      4.56×10^−2^   RFC4, MCM4, FEN1, MCM6
  0006260                                   DNA replication                                    4.15×10^−2^   RFC4, RNASEH2A, MCM4, FEN1, MCM6
                                                                                                             
  **B, Upregulated/hypomethylated genes**                                                                    
                                                                                                             
  **GO ID**                                 **GO term**                                        **FDR**       **Genes**
                                                                                                             
  000028                                    Nuclear division                                   3.63×10^−2^   RAD21, NUSAP1, NDC80, AURKA, CEP55, UBE2C, CDCA3
  0000279                                   M phase                                            4.61×10^−2^   RAD21, NUSAP1, NDC80, AURKA, CEP55, UBE2C, CDCA3
  0000278                                   Mitotic cell cycle                                 3.06×10^−2^   RAD21, NUSAP1, NDC80, AURKA, CEP55, CDKN3, UBE2C, CDCA3
  0000087                                   M phase of mitotic cell cycle                      2.68×10^−2^   RAD21, NUSAP1, NDC80, AURKA, CEP55, UBE2C, CDCA3

FDR, false discovery rate; GO, Gene Ontology.

###### 

KEGG pathway enrichment for methylation-related differentially expressed genes.

  A, Downregulated/hypermethylated genes                                                                    
  ----------------------------------------- --------------------------------------------- ----------------- --------------------------------------
  hsa04610                                  Complement and coagulation cascades           3.13×10^−3^       C8B, C7, KLKB1, C1R
  hsa00250                                  Alanine, aspartate and glutamate metabolism   3.81×10^−3^       ASPA, GOT1, ASS1
  hsa00380                                  Tryptophan metabolism                         6.04×10^−3^       AADAT, IDO2, KMO
  hsa00460                                  Cyanoamino acid metabolism                    6.82×10^−3^       GBA3, GGT5
  hsa00830                                  Retinol metabolism                            1.02×10^−2^       CYP4A11, CYP26A1, RDH16
  hsa04060                                  Cytokine-cytokine receptor interaction        2.67×10^−2^       CCL2, IL1RAP, NGFR, CXCL12, GHR
  hsa00270                                  Cysteine and methionine metabolism            2.91×10^−2^       GOT1, BHMT
  hsa00620                                  Pyruvate metabolism                           3.33×10^−2^       LDHD, ACOT12
  hsa00071                                  Fatty acid metabolism                         3.33×10^−2^       CYP4A11, ACADS
  hsa00983                                  Drug metabolism                               3.53×10^−2^       NAT2, UPP2
  hsa04115                                  p53 signaling pathway                         4.98×10^−2^       GADD45B, IGFBP3
                                                                                                            
  **B, Upregulated/hypomethylated genes**                                                                   
                                                                                                            
  **hsa03030**                              **DNA replication**                           **1.70×10^−5^**   **RFC4, RNASEH2A, MCM4, FEN1, MCM6**
                                                                                                            
  hsa04110                                  Cell cycle                                    1.79×10^−2^       RAD21, SFN, MCM4, MCM6
  hsa04120                                  Ubiquitin mediated proteolysis                4.67×10^−2^       UBE2C, UBE2Q1
  hsa05200                                  Pathways in cancer                            4.79×10^−2^       LAMC1, CTNNA1

KEGG, Kyoto Encyclopedia of Genes and Genomes.

###### 

Top 15 genes based on each topological characteristic.

  Node                                                    Degree   Node                                                    Closeness centrality   Node                                                    Average path length   Node                                                    Betweenness Centrality
  ------------------------------------------------------- -------- ------------------------------------------------------- ---------------------- ------------------------------------------------------- --------------------- ------------------------------------------------------- ------------------------
  NDC80                                                   18       FAT1                                                    1.00                   FAT1                                                    1.00                  FAT1                                                    1.00
  CDKN3^[a](#tfn3-mmr-20-03-2519){ref-type="table-fn"}^   16       SMAD5                                                   1.00                   SMAD5                                                   1.00                  FOS                                                     0.52
  AURKA^[a](#tfn3-mmr-20-03-2519){ref-type="table-fn"}^   16       CBFA2T3                                                 1.00                   CBFA2T3                                                 1.00                  CDKN3^[a](#tfn3-mmr-20-03-2519){ref-type="table-fn"}^   0.40
  UBE2C^[a](#tfn3-mmr-20-03-2519){ref-type="table-fn"}^   15       SPP2                                                    1.00                   SPP2                                                    1.00                  FEN1                                                    0.36
  NUSAP1                                                  15       FNIP1                                                   1.00                   FNIP1                                                   1.00                  MTR                                                     0.35
  RFC4                                                    14       WFDC1                                                   1.00                   WFDC1                                                   1.00                  LPL                                                     0.25
  KIF4A                                                   14       ECM1                                                    1.00                   ECM1                                                    1.00                  LPA                                                     0.18
  CEP55                                                   14       SLC22A1                                                 1.00                   SLC22A1                                                 1.00                  IGFBP3                                                  0.17
  FEN1                                                    13       SLC10A1                                                 1.00                   SLC10A1                                                 1.00                  TXNRD1                                                  0.16
  ATAD2                                                   13       ID1                                                     1.00                   ID1                                                     1.00                  SHBG                                                    0.16
  MCM4                                                    13       RRAGD                                                   1.00                   RRAGD                                                   1.00                  ASS1                                                    0.16
  FOS                                                     11       CTNNA1                                                  0.67                   CTNNA1                                                  1.50                  CCL2                                                    0.15
  MCM6                                                    11       LAMC1                                                   0.67                   LAMC1                                                   1.50                  ACADS                                                   0.15
  RNASEH2A                                                11       CDKN3^[a](#tfn3-mmr-20-03-2519){ref-type="table-fn"}^   0.28                   FOS                                                     3.54                  APOF                                                    0.14
  DEPDC1                                                  8        FOS                                                     0.28                   CDKN3^[a](#tfn3-mmr-20-03-2519){ref-type="table-fn"}^   3.54                  CANX                                                    0.14

Potential hub gene.

###### 

GO enrichment for genes in modules.

  A, Module 1                                                                            
  ----------------- ------------- ------------------------------------------------------ -----------------------------------------------------
  48015             1.86×10^−6^   Phosphoinositide-mediated signaling                    FEN1, RFC4, UBE2C, NDC80, AURKA
  278               3.01×10^−5^   Mitotic cell cycle                                     UBE2C, NUSAP1, NDC80, CEP55, AURKA, CDKN3
  6260              3.01×10^−5^   DNA replication                                        FEN1, RNASEH2A, RFC4, MCM4, MCM6
  22403             3.65×10^−5^   Cell cycle phase                                       UBE2C, NUSAP1, NDC80, CEP55, AURKA, CDKN3
  280               3.65×10^−5^   Nuclear division                                       UBE2C, NUSAP1, NDC80, CEP55, AURKA
  7067              3.65×10^−5^   mitosis                                                UBE2C, NUSAP1, NDC80, CEP55, AURKA
  87                3.65×10^−5^   M phase of mitotic cell cycle                          UBE2C, NUSAP1, NDC80, CEP55, AURKA
  7049              4.09×10^−5^   Cell cycle                                             UBE2C, NUSAP1, MCM6, NDC80, CEP55, AURKA, CDKN3
  51301             1.03×10^−4^   Cell division                                          UBE2C, NUSAP1, NDC80, CEP55, AURKA
  22402             1.03×10^−4^   Cell cycle process                                     UBE2C, NUSAP1, NDC8, CEP55, AURKA, CDKN3
  279               1.35×10^−4^   M phase                                                UBE2C, NUSAP1, NDC80, CEP55, AURKA
  35556             4.36×10^−3^   Intracellular signal transduction                      FEN1, RFC4, UBE2C, NDC80, AURKA
  6996              5.42×10^−3^   Organelle organization                                 UBE2C, KIF4A, NUSAP1, NDC80, CEP55, AURKA
  34645             1.06×10^−2^   Cellular macromolecule biosynthetic process            FEN1, RNASEH2A, RFC4, MCM4, MCM6
  9059              1.08×10^−2^   Macromolecule biosynthetic process                     FEN1, RNASEH2A, RFC4, MCM4, MCM6
  23034             1.41×10^−2^   Intracellular signaling pathway                        FEN1, RFC4, UBE2C, NDC80, AURKA
  90304             2.84×10^−2^   Nucleic acid metabolic process                         FEN1, RNASEH2A, RFC4, MCM4, MCM6
  44249             4.55×10^−2^   Cellular biosynthetic process                          FEN1, RNASEH2A, RFC4, MCM4, MCM6
                                                                                         
  **B, Module 2**                                                                        
                                                                                         
  **GO ID**         **P~corr~**   **GO term**                                            **Genes in test set**
                                                                                         
  10273             9.41×10^−3^   Detoxification of copper ion                           MT2A
  10038             9.41×10^−3^   Response to metal ion                                  MT2A, MT1X
  10035             1.12×10^−2^   Response to inorganic substance                        MT2A, MT1X
  6882              1.12×10^−2^   Cellular zinc ion homeostasis                          MT2A
  55069             1.12×10^−2^   Zinc ion homeostasis                                   MT2A
  6878              1.12×10^−2^   Cellular copper ion homeostasis                        MT2A
  55070             1.12×10^−2^   Copper ion homeostasis                                 MT2A
  7263              1.37×10^−2^   Nitric oxide mediated signal transduction              MT2A
  46688             1.48×10^−2^   Response to copper ion                                 MT2A
                                                                                         
  **C, Module 3**                                                                        
                                                                                         
  **GO ID**         **P~corr~**   **GO term**                                            **Genes in test set**
                                                                                         
  30334             1.28×10^−2^   Regulation of cell migration                           CXCL12, IGFBP3, THY1
  51270             1.28×10^−2^   Regulation of cellular component movement              CXCL12, IGFBP3, THY1
  40012             1.28×10^−2^   Regulation of locomotion                               CXCL12, IGFBP3, THY1
  42325             3.08×10^−2^   Regulation of phosphorylation                          GHR, IGFBP3, THY1
  19220             3.08×10^−2^   Regulation of phosphate metabolic process              GHR, IGFBP3, THY1
  51174             3.08×10^−2^   Regulation of phosphorus metabolic process             GHR, IGFBP3, THY1
  45595             3.08×10^−2^   Regulation of cell differentiation                     GHR, IGFBP3, THY1
  7155              3.56×10^−2^   Cell adhesion                                          CXCL12, THY1, IGFALS
  22610             3.56×10^−2^   Biological adhesion                                    CXCL12, THY1, IGFALS
  32879             3.64×10^−2^   Regulation of localization                             CXCL12, IGFBP3, THY1
  50793             3.69×10^−2^   Regulation of developmental process                    GHR, IGFBP3, THY1
  48522             3.81×10^−2^   Positive regulation of cellular process                GHR, CXCL12, IGFBP3, THY1
  48518             4.28×10^−2^   Positive regulation of biological process              GHR, CXCL12, IGFBP3, THY1
  51239             4.29×10^−2^   Regulation of multicellular organismal process         GHR, IGFBP3, THY1
  10646             4.53×10^−2^   Regulation of cell communication                       GHR, IGFBP3, THY1
  7166              4.93×10^−2^   Cell surface receptor linked signaling pathway         GHR, CXCL12, THY1
                                                                                         
  **D, Module 4**                                                                        
                                                                                         
  **GO ID**         **P~corr~**   **GO term**                                            **Genes in test set**
                                                                                         
  19752             7.81×10^−8^   Carboxylic acid metabolic process                      BHMT, GOT1, MTR, ALDH8A1, ACADS, ASPA, ASS1
  43436             7.81×10^−8^   Oxoacid metabolic process                              BHMT, GOT1, MTR, ALDH8A1, ACADS, ASPA, ASS1
  6082              7.81×10^−8^   Organic acid metabolic process                         BHMT, GOT1, MTR, ALDH8A1, ACADS, ASPA, ASS1
  42180             7.81×10^−8^   Cellular ketone metabolic process                      BHMT, GOT1, MTR, ALDH8A1, ACADS, ASPA, ASS1
  6520              2.23×10^−6^   Cellular amino acid metabolic process                  BHMT, GOT1, MTR, ASPA, ASS1
  44106             6.48×10^−6^   Cellular amine metabolic process                       BHMT, GOT1, MTR, ASPA, ASS1
  44281             1.21×10^−5^   Small molecule metabolic process                       BHMT, GOT1, MTR, ALDH8A1, ACADS, ASPA, ASS1
  6519              1.21×10^−5^   Cellular amino acid and derivative metabolic process   BHMT, GOT1, MTR, ASPA, ASS1
  9308              1.89×10^−5^   Amine metabolic process                                BHMT, GOT1, MTR, ASPA, ASS1
  44283             2.33×10^−5^   Small molecule biosynthetic process                    BHMT, GOT1, MTR, ALDH8A1, ASS1
  44237             1.82×10^−3^   Cellular metabolic process                             BHMT, GOT1, TXNRD1, MTR, ALDH8A1, ACADS, ASPA, ASS1
  8152              5.73×10^−3^   Metabolic process                                      BHMT, GOT1, TXNRD1, MTR, ALDH8A1, ACADS, ASPA, ASS1
  44249             5.73×10^−3^   Cellular biosynthetic process                          BHMT, GOT1, MTR, ALDH8A1, ASS1
  9058              6.30×10^−3^   Biosynthetic process                                   BHMT, GOT1, MTR, ALDH8A1, ASS1
  34641             9.55×10^−3^   Cellular nitrogen compound metabolic process           BHMT, GOT1, MTR, ASPA, ASS1
  6807              1.19×10^−2^   Nitrogen compound metabolic process                    BHMT, GOT1, MTR, ASPA, ASS1
  44238             1.71×10^−2^   Primary metabolic process                              BHMT, GOT1, MTR, ALDH8A1, ACADS, ASPA, ASS1

GO, Gene Ontology; P~corr~, corrected P-value.
